LivaNova PLC (LIVN)
Nasdaq · Healthcare · Medical Devices
$76.43+1.81%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $4.2B
- P/E (trailing)
- 22.6
- Forward P/E
- 16.3
- 52-week range
- $48.82 – $85.76
- 52-week change
- +43.95%
- EPS (trailing)
- $3.38
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $1.4B (+10.75%)
- Net income
- −$243M
- Operating margin
- 14.4%
- Diluted EPS
- −$4.45
- Free cash flow
- $173M
From the company’s annual report on SEC EDGAR.
About LivaNova PLC
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and depression. This segment also includes the development and clinical testing of aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, hospitals, other healthcare professionals and medical institutions, and healthcare providers.
Headquarters: Gloucester, United Kingdom · 3,300 employees · livanova.com